Disclosures

Alaa H. Addasi, MD
No significant financial relationship to disclose
Frederick R. Appelbaum, MD
Advisory board for and honoraria from Abgenix,
Celgene, Immunex, and Wyeth Ayerst

Patrick J. Flynn, MD
Advisory Board of Aventis, Sanofi, Bristol-Myers Squibb,
AstraZeneca, Novartis, Genentech, Lilly, Supergen,
Berlex, GlaxoSmithKline & Glaxo, and IDEC; honoraria
from Sanofi, Genentech, Novartis, Amgen
Arlene A. Forastiere, MD
Advisory Board of Genetronics; ownership interests
(including stock options but excluding indirect investments through mutual funds and the like) in
Genetronics; research funding from Pharmacia/Pfizer,
Bristol-Myers Squibb, and Genentech

Ernest C. Borden, MD
No significant financial relationship to disclose
Otis W. Brawley, MD
Consultant for GlaxoSmithKline and Merck
Jan Buckner, MD
Consultant for NeoPharm and Anti-sense Pharma;
research funding from Pharmacia and Wyeth Ayerst

Stephen J. Forman, MD
No significant financial relationship to disclose

G. Thomas Budd, MD
Research funding from Novartis, Genentech, Pfizer, and
AstraZeneca; honoraria from Aventis, Novartis, and
AstraZeneca

Edward P. Gelmann, MD
Ownership interests in Genta Care; research funding
from the National Cancer Institute and the National
Institute of Environmental Health Sciences

Paul B. Chapman, MD
Research funding from ImClone

Parkash Gill, MD
Ownership interests in Vosgene and Cancer Vax

Bruce D. Cheson, MD
Research funding from IDEC Pharmaceuticals;
honoraria from Benex, IDEC Pharmaceuticals, and
Genentech

William J. Gradishar, MD
No significant financial relationship to disclose

Gary I. Cohen, MD, FACP

No significant financial relationship to disclose

William N. Hait, MD, PhD

No significant financial relationship to disclose

Dale H. Cowan, MD, JD

Consultant for and honoraria from AstraZeneca

Gabriel N. Hortobagyi, MD, FACP

Consultant for Genentech and RPI; research funding
from RPI and Bristol-Myers Squibb; honoraria from
Genentech, Aventis, AstraZeneca, Novartis, and BristolMyers Squibb

David Cunningham, MD, FRCP

Consultant for Aventis, Roche, Sanofi, and Merck
Russell F. DeVore III, MD
No significant financial relationship to disclose

Orion M. Howard, MD
No significant financial relationship to disclose

Peter D. Eisenberg, MD
Research funding from GlaxoSmithKline, MGI Pharma,
and Merck; honoraria from MGI Pharma
Paul F. Engstrom, MD
No significant financial relationship to disclose
Nancy R. Feldman, MD
Research funding from
Genentech

viii

GlaxoSmithKline

Stuart A. Grossman, MD
No significant financial relationship to disclose

and

Karen L. Kelly, MD
Consultant for AstraZeneca, Bristol-Myers Squibb,
Pharmacia, Lilly, and Aventis; research funding from
Aventis, Alphacel, Cell Pathways, Pharmacia,
AstraZeneca, and Schering-Plough; honoraria from
AstraZeneca and Bristol-Myers Squibb
Catherine E. Klein, MD
No significant financial relationship to disclose

Corey J. Langer, MD, FACP

Consultant for ImClone, Bristol-Myers Squibb, Aventis,
Pharmacia, Intrabiotics, GlaxoSmithKline, Pharmacyclics,
Amgen, and AstraZeneca; research funding from BristolMyers Squibb, Pharmacia, Lilly, Schering-Plough Research
Institute, Aventis, Amgen, Cell Therapeutics Inc.,
OrthoBiotech, Celgene, Vertex, Genentech, AstraZeneca,
and Pfizer; honoraria from Bristol-Myers Squibb, Aventis,
Pharmacia, Lilly, and OrthoBiotech

Howard I. Scher, MD
Consultant for Bristol-Myers Squibb, Conforma
Therapeutics, Genentech, Novartis, and ProQuest
Investments; ownership interests (including stock options
but excluding indirect investments through mutual funds
and the like) in Eli Lilly, Cell Therapeutics, Vidamed,
Proquest, Conforma, and Genta; research funding from
AstraZeneca, Bristol-Myers Squibb, CaP CURE, and
Millennium Pharmaceuticals; honoraria from AstraZeneca

Stuart M. Lichtman, MD
Honoraria from OrthoBiotech and Amgen

Joan Schiller, MD
Advisory Board for AstraZeneca, Lilly, Pharmacia, and
Genentech; research funding from AstraZeneca, Lilly,
and Genentech; honoraria from AstraZeneca, Lilly,
Pharmacia, and Genentech

Charles Loprinzi, MD
No significant financial relationship to disclose
Laurie J. Lyckholm, MD
No significant financial relationship to disclose
Jewraj G. Maheshwari, MD
Advisory Board for Eli Lilly and Merck
Robert Maki, MD, PhD
Research funding from Pharm Mar and Pharmacia
Maurie Markman, MD
Paid expert testimony for Eli Lilly; research funding from
Bristol-Myers Squibb, Aventis, Eli Lilly, Pharmacia,
Celgene, GlaxoSmithKline, and OrthoBiotech; honoraria
from Bristol-Myers Squibb, Aventis, Eli Lilly, GlaxoSmithKline, Intermune, and OrthoBiotech
John Marshall, MD
Consultant for Sanofi, Roche, Pharmacia, and B-I;
Advisory Board for Sanofi, Roche, Pharmacia, and B-I;
research funding from Roche and Pharmacia; honoraria
from Roche, Pharmacia, and Sanofi
Joanne Mortimer, MD
Advisory Board for Genentech; honoraria from
AstraZeneca and Pharmacia
Edith A. Perez, MD
Research funding from Genentech, Bristol-Myers
Squibb, Aventis, Lilly, and Pfizer; honoraria from BristolMyers Squibb, Genentech, and Pfizer
David G. Pfister, MD
Consultant for Aventis and Onyx; research funding from
ImClone
John E. Pippen, Jr., MD, FACP
Honoraria from AstraZeneca, Novartis, and Aventis

Lynn M. Schuchter, MD
No significant financial relationship to disclose
Scott M. Schuetze, MD, PhD
Consultancy with Neo RX Corporation; research funding from Immunex and Aventis
Jennifer E. Schwartz, MD
Ownership interests in Merck and Pfizer
Michael Schwartz, MD
No significant financial relationship to disclose
Visaharan Sivasubramaniam, MD
No significant financial relationship to disclose
Marvin J. Stone, MD
Ownership interests in US Oncology
Christopher J. Sweeney, MBBS
Research funding from Aventis
Martin S. Tallman, MD
Consultant for and honoraria from Cell Therapeutics
and Wyeth Ayerst Oncology
James Tate Thigpen, MD
Consultant for Bristol-Myers Squibb, GlaxoSmithKline,
Novartis, Eli Lilly, OrthoBiotech, Intermune, Cell
Therapeutics, Medimmune, Amgen, and Aventis
Robert F. Todd, MD, PhD
Ownership interests in Amgen, Merck, Pfizer, BristolMyers Squibb, Johnson and Johnson, and Abbott
Laboratories

Richard J. Robbins, MD
Honoraria from Genzyme

Alan P. Venook, MD
Consultant for Nexcura and Metabasis; research funding
from Ferx, Genentech, Amgen, Tularik, and Novartis;
honoraria from Roche

Nicholas J. Robert, MD
No significant financial relationship to disclose

Charles F. von Gunten, MD, PhD

No significant financial relationships to disclose

Mace L. Rothenberg, MD
No significant financial relationship to disclose

Jeffrey L. Wolf, MD
No significant financial relationship to disclose

ix